Lung cancer trials in China

In China 1143 Also abroad 2744

1,143 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer
Where
Chengdu, Luzhou, Meishan, Nanchong, Suining, Zigong
Age
18 years to 80 years
People
40
Run by
West China Hospital
See details and how to joinNCT07855965
Phase 2Taking people
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Where
Beijing
Age
18 years and over
People
243 worldwide
Run by
Shanghai Henlius Biotech
See details and how to joinNCT06907615 · EU 2025-523803-31-00
Phase 1/2Taking people
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Where
Guangzhou, Kunming
Age
18 years and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00
No phaseNot yet taking people in China
Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery
Where
Hangzhou, Jiaxing
Age
18 years and over
People
566
Run by
Diansan Su
See details and how to joinNCT07849400
No phaseNot yet taking people in China
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
Where
Hangzhou
Age
75 days and over
People
30
Run by
Zhejiang Cancer Hospital
See details and how to joinNCT07849712
Phase 2Not yet taking people in China
Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer
Where
Wuhan
Age
18 years to 75 years
People
12
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07845916
Phase 2Taking people
Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
Where
Beijing
Age
18 years and over
People
50
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07848243
No phaseTaking people
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
Where
Beijing
Age
18 years to 75 years
People
120
Run by
Peking University First Hospital
See details and how to joinNCT07039474
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haerbin, Hangzhou, Hefei, Jiamusi, Jinan, Langfang, Lanzhou, Linyi, Liuzhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wuhan, Xuzhou, Yantai, Zhengzhou
Age
18 years and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
Phase 2Taking people
A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer
Where
Quzhou
Age
18 years to 75 years
People
112
Run by
People's Hospital of Quzhou
See details and how to joinNCT07647094
Phase 1Not yet taking people in China
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
Where
Shenzhen
Age
18 years and over
People
80 worldwide
Run by
Pfizer
See details and how to joinNCT07663630 · EU 2026-526002-32-00
No phaseTaking people
Cardiorespiratory Fitness After Lobectomy Versus Sublobar Resection
Where
Wuhan
Age
18 years and over
People
604
Run by
Tongji Hospital
See details and how to joinNCT07841249
Phase 2Not yet taking people in China
Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC
Where
Guangzhou
Age
18 years and over
People
117
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT07842471
Phase 1Not yet taking people in China
Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance
Where
Beijing
Age
18 years and over
People
24
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07842887
Phase 1/2Taking people
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
Where
Guangzhou
Age
18 years to 75 years
People
200
Run by
Hangzhou DAC Biotechnology Co., Ltd.
See details and how to joinNCT07559929
Phase 3Not yet taking people in China
A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Where
Nanchang
Age
18 years to 75 years
People
416
Run by
Shanghai Jeyou Pharmaceutical Co., Ltd.
See details and how to joinNCT07833202
Phase 1Taking people
A Study of DXC014 in Patients With Advanced Solid Tumors.
Where
Beijing, Changsha, Hangzhou, Nanchang, Qingdao
Age
18 years and over
People
150
Run by
Hangzhou DAC Biotechnology Co., Ltd.
See details and how to joinNCT07177937
No phaseTaking people
Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC
Where
Wuhan
Age
18 years to 75 years
People
100
Run by
Tongji Hospital
See details and how to joinNCT07837739
Phase 1/2Not yet taking people in China
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
Where
Shanghai
Age
18 years to 80 years
People
26
Run by
RemeGen Co., Ltd.
See details and how to joinNCT05745740
Phase 1Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Where
Guangzhou, Shanghai
Age
18 years and over
People
232 worldwide
Run by
AbbVie
See details and how to joinNCT06858813 · EU 2024-518012-39-00
Phase 2Taking people
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer
Where
Jiangmen
Age
18 years to 75 years
People
43
Run by
Jiangmen Central Hospital
See details and how to joinNCT07583550
No phaseNot yet taking people in China
AI-Assisted Chest CT Interpretation Across the Lung Cancer Care Continuum
Where
Wuhan
Age
18 years and over
People
15
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07829640
Phase 3Not yet taking people in China
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
Where
Shanghai
Age
18 years to 85 years
People
600
Run by
Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT07831863
Phase 3Taking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuyang, Fuzhou, Ganzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hohhot, Jinan, Kunming, Luoyang, Luzhou, Nanchang, Nanning, Nanyang, Qingdao, Shanghai, Shenyang, Tai’an, Taizhou, Tianjin, Weifang, Weihui, Wenzhou, Xi’an, Zhengzhou, Zhuzhou
Age
18 years and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Where
Beijing, Hangzhou, Jinan, Linhai, Linyi, Nanchang, Nanning, Xiamen
Age
18 years and over
People
182 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00